Invex Therapeutics Company Description

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.

It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial.

The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Subiaco, Australia.